Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 2-28 (IGKV2-28) is the variable region of the kappa light chain of immunoglobulins (antibodies)[1][2][8]. Its primary function is to contribute to the formation of the antigen-binding site of immunoglobulins, where it participates in recognizing and binding to specific antigens, forming part of the adaptive immune response[1][2][6]. This region undergoes V-(D)-J recombination and somatic hypermutation, processes that enable the immune system to generate a vast diversity of antibody specificities[2][6]. IGKV2-28 is one of many variable region genes that encode the immunoglobulin light chain's variable domain, essential for the specificity and affinity of antigen binding[2][6]. It is not considered a therapeutic target, receptor, enzyme, or classic disease biomarker, but rather a structural component of antibodies[2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 2-28 (IGKV2-28).